Kidney Cancer (Renal Cell Carcinoma)

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, arising from the lining cells of the renal tubules. It accounts for approximately 90% of all kidney cancers. Globally, around 430,000 new cases are diagnosed each year. RCC is more common in men than women and is most frequently diagnosed in adults over 50. A growing proportion of cases are now detected incidentally on abdominal imaging performed for unrelated reasons, often at an early and potentially curable stage.

The most common subtype is clear cell RCC, which accounts for approximately 75% of cases and is driven by VHL gene loss. Papillary RCC (Types 1 and 2) accounts for about 10–15%, followed by chromophobe RCC (~5%). Rare subtypes include TFE3-translocation RCC, collecting duct carcinoma, and renal medullary carcinoma. Subtype identification by expert pathology is critical, as each has distinct molecular features and responds differently to systemic therapies.

For localized RCC confined to the kidney, surgery is the primary and often curative treatment. Partial nephrectomy (kidney-sparing surgery) is preferred for tumors ≤ 7 cm to maximize preservation of kidney function. Radical nephrectomy is performed for larger or more centrally located tumors. For small renal masses in patients who are not surgical candidates, thermal ablation (radiofrequency ablation or cryoablation) is an accepted alternative. Active surveillance is occasionally appropriate for very small, indolent-appearing tumors in older or frail patients.

Metastatic RCC is now treated with combination immunotherapy and targeted therapy. First-line regimens include nivolumab + cabozantinib, pembrolizumab + axitinib, pembrolizumab + lenvatinib, and nivolumab + ipilimumab (for intermediate/poor-risk patients). These combinations have replaced sunitinib monotherapy as the standard of care. Regimen selection is guided by the IMDC risk classification, RCC subtype, and individual patient factors. Belzutifan, a HIF-2α inhibitor, is an emerging option in VHL-mutant disease.

The VHL (von Hippel-Lindau) gene is a tumor suppressor that regulates the HIF (hypoxia-inducible factor) pathway. Biallelic inactivation of VHL is found in over 90% of clear cell RCC and leads to overexpression of VEGF and other growth factors, driving tumor angiogenesis. This is the mechanistic basis for VEGF-targeted therapies (sunitinib, pazopanib, axitinib). Germline VHL mutations cause VHL syndrome, a hereditary condition associated with multiple bilateral renal tumors. Belzutifan, which directly inhibits HIF-2α, represents the most targeted approach to this molecular pathway to date.

Most kidney cancers are sporadic (non-hereditary), but a meaningful minority arise in the setting of germline predisposition syndromes. These include VHL syndrome (germline VHL mutations), Hereditary Papillary RCC (MET mutations), Birt-Hogg-Dubé syndrome (FLCN mutations), Hereditary Leiomyomatosis and RCC (FH mutations), and SDH-deficient RCC syndromes. Features that suggest a hereditary cause include young age at diagnosis, bilateral or multifocal tumors, or a family history of kidney cancer. Genetic counseling and germline testing are recommended in these circumstances.

Adjuvant therapy is treatment given after surgery to reduce the risk of cancer recurrence. For high-risk resected RCC (stage T2 grade 4, T3, T4, or lymph node-positive disease), adjuvant pembrolizumab (an anti-PD-1 immunotherapy) is approved and has demonstrated a significant improvement in disease-free survival. Not all patients require adjuvant therapy — patients with lower-risk resected disease are generally managed with surveillance. The decision should be made in consultation with a specialist oncologist based on individual risk features.

After nephrectomy for localized disease, surveillance typically includes regular CT imaging of the chest, abdomen, and pelvis at intervals determined by stage and risk (every 3–6 months initially, then annually). Renal function, blood pressure, and urinalysis are monitored given the impact of nephrectomy on remaining kidney function. For patients on systemic therapy for metastatic disease, CT imaging is typically performed every 2–3 months to assess treatment response. Brain MRI is performed if neurologic symptoms develop. Lifelong surveillance is recommended given the possibility of late recurrence.

Yes. CancerFax supports kidney cancer patients at every stage — from organizing imaging and pathology reports for specialist review, to coordinating second opinions from urologic oncology and medical oncology teams in India and internationally. For patients with metastatic or rare-subtype RCC, CancerFax can identify access pathways to advanced therapy combinations and clinical trials, including programs in China where agents such as savolitinib for MET-driven papillary RCC are available. Whether you are navigating a new diagnosis, considering surgery at a specialist center, or facing disease progression, CancerFax is here to help guide your next steps.